Scarica l'app Stockscreener
73.00
0.60%
0.59
Kymera Therapeutics Inc Borsa (KYMR) Ultime notizie
Kymera Therapeutics (KYMR) Downgraded by Wolfe Research | KYMR S - GuruFocus
Kymera Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13 - The Manila Times
Kymera Therapeutics CEO to unveil 2026 milestones at JPMorgan event - Traders Union
Wolfe Research downgrades Kymera Therapeutics stock rating on lack of catalysts - Investing.com UK
KYMR Skyrockets 82.4% in a Year: More Upside Potential in 2026? - Finviz
Kymera Therapeutics stock extends slide as KYMR closes down 6.5% — what investors watch next - ts2.tech
KYMR Stock Falls -14% With A 7-day Losing Spree On Significant Insider Selling - Trefis
Kymera Therapeutics stock slides nearly 7% after CEO share-sale filing — what KYMR investors watch next - ts2.tech
Kymera Therapeutics (NASDAQ:KYMR) Trading Down 4.3%What's Next? - MarketBeat
Insider Buying: Smart Money Just Spent +$100M on These 3 Stocks - Investing.com
Kymera Therapeutics (KYMR) Sees 4% Drop in Stock Price - GuruFocus
Insider Buying: Smart Money Just Spent +$100M on These 3 Stocks - MarketBeat
The Technical Signals Behind (KYMR) That Institutions Follow - Stock Traders Daily
Kymera Therapeutics (NASDAQ:KYMR) CEO Nello Mainolfi Sells 30,000 Shares - MarketBeat
Kymera Therapeutics Insider Sold Shares Worth $2,341,939, According to a Recent SEC Filing - marketscreener.com
Kymera Therapeutics (NASDAQ: KYMR) CEO reports option exercise and share sale - Stock Titan
Kymera Therapeutics Earnings Notes - Trefis
Kymera Therapeutics (KYMR) stock falls today as biotech slips — what traders are watching - ts2.tech
Kymera Therapeutics announces results from BroADen Phase 1b trial of KT-621 - MSN
Citi Raises Kymera (KYMR) Price Target After Positive Drug Data, Keeps Buy Rating - MSN
Kymera draws upgrades after early-stage data for anti-inflammatory agent - MSN
B. Riley Securities Maintains Kymera Therapeutics (KYMR) Buy Recommendation - Nasdaq
Why Kymera Therapeutics Stock Is Sliding Despite Hype - TipRanks
KYMR: B. Riley Securities Raises Price Target for Kymera Therape - GuruFocus
B. Riley Raises Price Target on Kymera Therapeutics to $117 From $80, Keeps Buy Rating - marketscreener.com
Can Kymera Therapeutics Inc. stock hit analyst price targets2025 Valuation Update & Daily Growth Stock Tips - Улправда
Squarepoint Ops LLC Cuts Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat
What momentum indicators show for Kymera Therapeutics Inc. stockDividend Hike & Low Risk Entry Point Guides - ulpravda.ru
Kymera Therapeutics (NASDAQ:KYMR) Shares Down 3.4%Here's What Happened - MarketBeat
Can Kymera Therapeutics Inc. stock deliver consistent earnings growth - Улправда
Kymera Therapeutics Insider Sold Shares Worth $2,264,480, According to a Recent SEC Filing - marketscreener.com
Share Offerings Prompt Huge Insider Buying in These 3 Biotechs - 24/7 Wall St.
Why Analysts See Kymera Therapeutics Differently After KT 621 Momentum And Rising Fair Value - Yahoo Finance
RBC Capital Maintains Kymera Therapeutics (KYMR) Outperform Recommendation - Nasdaq
Kymera Poised to Become Leading Firm in Multiple Inflammation & Immunology Indications, RBC Says - marketscreener.com
RBC Capital Raises Price Target for Kymera Therapeutics (KYMR) | - GuruFocus
RBC Raises Price Target on Kymera Therapeutics to $103 From $70, Keeps Outperform, Speculative Risk - marketscreener.com
Kymera Therapeutics stock price target raised to $103 from $70 at RBC Capital - Investing.com Canada
Kymera's eczema drug gets fast track designation in the United States - MSN
Obesity data, Kymera and FDA sentiment survey results — a BioCentury podcast - BioCentury
Kymera gains fast track status for oral candidate KT-621 for eczema - MSN
Kymera Therapeutics Insider Sold Shares Worth $21,699,044, According to a Recent SEC Filing - marketscreener.com
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. - Barron's
Kymera Therapeutics (NASDAQ:KYMR) Director Bruce Booth Sells 678 Shares - MarketBeat
Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) Director Sells 6,101 Shares of Stock - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) Director Bruce Booth Sells 229,809 Shares - MarketBeat
Eventide Asset Management LLC Increases Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat
BVF Inc. IL Boosts Stake in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics director Booth sells $21.7 million in stock By Investing.com - Investing.com Canada
Kymera Therapeutics director Booth sells $21.7 million in stock - Investing.com
Kymera Therapeutics Inc. (KYMR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Kymera Therapeutics (NASDAQ:KYMR) Director Buys $172,499,918.00 in Stock - MarketBeat
Owner Atlas Venture Fund X LP Files To Sell 570 Of Kymera Therapeutics Inc [KYMR] - TradingView — Track All Markets
Kymera Therapeutics Soars on Robust KT-621 Trial Results - timothysykes.com
Kymera jumps on early-stage data for eczema candidate KT-621 - MSN
Kymera's Eczema Drug Gets Fast Track Designation in the United States - Yahoo Finance
Kymera Therapeutics announces $500M proposed public offering - MSN
Redmile Group LLC Trims Stock Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Frontier Capital Management Co. LLC Grows Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Mizuho Maintains Kymera Therapeutics (KYMR) Outperform Recommendation - Nasdaq
Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise ... - Enidnews.com
Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Manila Times
2.47%
0.03%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):